Sharon Diskin

Associate Professor

University of Pennsylvania
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (26)

Table S7: Number of TARGET samples with WGS and SCNA events per cancer identified by GISTIC, Table S8: Differential expression of genes in samples with and without SCNA, Table S9: Number of samples with SVs in lncRNAs

Year:

2025

Table S15: Data integration using multi-dimensional analysis to prioritize functional lncRNAs in each cancer, Table S16: Prioritized lncRNAs and predicted lncRNA target genes and pathways in NBL, Table S17: GSEA Analysis: MSigDB Hallmarks enriched across genes impacted by siTBX2-AS1 or siTBX2 treatment in NLF

Year:

2025

Table S10: Statistics for input and output variables of lncMod analysis (xls file), Table S11: Significantly dysregulated lncMod triplets, Table S12: lncRNA TF associations ranked by # target genes

Year:

2025

Table S1: TARGET clinical sample and RNA-sequencing characteristics, Table S2: Genomic loci for lncRNA and protein coding genes in this study, Table S3: Number and types of genes expressed per cancer

Year:

2025

Table S4: Top 10 expressed lncRNAs across TARGET cancers and GTEx tissues, Table S5: Tissue specificity index (tau score) annotation per gene, Table S6: Validation of tissue specific lncRNAs based on tau score analysis in alternate NBL datasets

Year:

2025

Despite intensive, multimodal therapy, only half of children diagnosed with high-risk neuroblastoma will survive five years, and survivors harbor significant short- and long-term treatment-related co-morbidities. Although monoclonal antibody therapy targeting GD2 has improved outcomes, GD2-directed immunotherapy remains one of the only FDA-approved immunotherapies for pediatric cancer, and therapy is toxic due to GD2 expression on pain fibers. Thus, there is a critical need to uncover new immunotherapy targets in neuroblastoma. ALCAM is a cell adhesion molecule that promotes tumor growth in a variety of cancers and is highly expressed in neuroblastoma. We generated three inducible CRISPRi cell lines to deplete ALCAM and elucidate its role in neuroblastoma. Depletion of ALCAM reduced cell growth, reduced Ki-67 staining, and increased cleaved PARP. To determine the mechanism of ALCAM overexpression, we used ChIP-sequencing to show MYCN oncoprotein binding at the ALCAM promoter. We generated luciferase reporters from the ALCAM promoter and a putative upstream (10kb) enhancer, which we defined using Promoter-based Capture-C. Treatment with the MYC(N)/MAX dimerization inhibitor MYCi975 reduced ALCAM expression by immunoblotting and luciferase signal from the ALCAM promoter. We validated the activity of the upstream enhancer and uncovered an AP-1 binding motif that is critical for enhancer activity. Finally, as ALCAM is expressed in several normal tissues, we investigated an ALCAM-targeted conditionally activated antibody drug conjugate (ADC), CX-2009 (praluzatamab ravtansine), which delayed tumor growth in two out of three PDX models. Together, these findings credential ALCAM as an immunotherapeutic target in neuroblastoma.

Year:

2025

We provide data showing the germline predisposition structural variants (SV) involving MYCN and RAF1::TMEM40 reported by Gillani et al. (2025) in pediatric solid tumors are confounded by circulating tumor DNA (ctDNA) and enrichment for Hispanic or Latino ancestry, respectively. We suggest that future germline studies should ensure analyses of tumor-in-normal contamination for non-polymorphic markers and careful examination of population stratification for polymorphic markers to ensure clinical relevance.

Year:

2025

Purpose: DROSHA , DGCR8 , and DICER1 regulate miRNA biogenesis and are commonly mutated in cancer. Although DGCR8 and DICER1 germline pathogenic variants (GPV) cause autosomal dominant tumor predisposition, no association between DROSHA GPVs and clinical phenotypes has been reported. Experimental Design: After obtaining informed consent, sequencing was performed on germline and tumor samples from all patients. The occurrence of germline DROSHA GPVs was investigated in large pediatric and adult cancer datasets. The population prevalence of DROSHA GPVs was investigated in the UK Biobank and Geisinger DiscovEHR cohorts. Results: We describe nine children from eight families with heterozygous DROSHA GPVs and a diagnosis of pineoblastoma ( n = 8) or Wilms tumor ( n = 1). A somatic second hit in DROSHA was detected in all eight tumors analyzed. All pineoblastoma tumors analyzed were classified as miRNA processing–altered 1 subtype. We estimate the population prevalence of germline DROSHA loss-of-function variants to be 1:3,875 to 1:4,843 but find no evidence for increased adult cancer risk. Conclusions: This is the first report of DROSHA- related tumor predisposition. As pineoblastoma and Wilms tumor are also associated with DICER1 GPVs, our results suggest that the tissues of origin for these tumors are uniquely tolerant of general miRNA loss. The miRNA processing–altered 1 pineoblastoma subtype is associated with older age of diagnosis and better outcomes than other subtypes, suggesting DROSHA GPV status may have important clinical and prognostic significance. We suggest that genetic testing for DROSHA GPVs be considered for patients with pineoblastoma, Wilms tumor, or other DICER1 -/ DGCR8 -related conditions and propose surveillance recommendations through research studies for individuals with DROSHA GPVs.

Year:

2025

The contribution of rare pathogenic/likely pathogenic (P/LP) germline variants to pediatric central nervous system (CNS) tumor development remains understudied. Here, we characterized the prevalence and clinical significance of germline P/LP variants in cancer predisposition genes across 830 CNS tumor patients from the Pediatric Brain Tumor Atlas (PBTA). We identified germline P/LP variants in 23.3% (193/830) of patients and the majority (137/193) lacked clinical reporting of genetic tumor syndromes. Among P/LP carriers, 34.6% had putative somatic second hits or loss of function tumor alterations. Finally, we linked pathogenic germline variation with novel somatic events and patient survival to highlight the impact of germline variation on tumorigenesis and patient outcomes.

Year:

2025

Table S1: TARGET clinical sample and RNA-sequencing characteristics, Table S2: Genomic loci for lncRNA and protein coding genes in this study, Table S3: Number and types of genes expressed per cancer

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (35)

Sharon E. Plon

Professor and Assistant Dean

Baylor College of Medicine

UNITED STATES
View details

Berkley E. Gryder

Case Western Reserve University

UNITED STATES
View details

Adam Resnick

Director

University of Pennsylvania

UNITED STATES
View details

Sebastian Waszak

Tenure Track Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Struan Grant

Professor of Genetics and Pediatrics

University of Pennsylvania

UNITED STATES
View details

Dominique Stoppa-Lyonnet

Institut Curie

FRANCE
View details

Kuan-lin Huang

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Sarah Tasian

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Miriam Bornhorst

Ann and Robert H Lurie Children's Hospital of Chicago

UNITED STATES
View details

威 李

Assistant professor

University of Pittsburgh

UNITED STATES
View details

Angela Waanders

Associate Professor

Ann and Robert H Lurie Children's Hospital of Chicago

UNITED STATES
View details

Frank Lin

Baylor College of Medicine Department of Pediatrics

UNITED STATES
View details

Javed Khan

National Institutes of Health

UNITED STATES
View details

Kara Maxwell

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Gregg Morin

Associate Professor

The University of British Columbia

CANADA
View details

Elizabeth J Perlman

Ann and Robert H Lurie Children's Hospital of Chicago

UNITED STATES
View details

Soheil Meshinchi

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Kenneth S. Chen

University of Texas Southwestern Medical Center

UNITED STATES
View details

Jo Lynne Rokita

Director, Brain Tumor Institute Bioinformatics Core

Children's National Health System

UNITED STATES
View details

Deanne Taylor

Research Associate Professor

University of Pennsylvania

UNITED STATES
View details

John Maris

PI

University of Pennsylvania

UNITED STATES
View details

Carl Koschmann

University of Michigan Medical School

UNITED STATES
View details

Giselle L. Saulnier Sholler

-

UNITED STATES
View details

Marilyn Li

Associate Chair and Vice Chief of Division of Genomic Diagnoatics

Children's Hospital of Philadelphia

UNITED STATES
View details

Jinghui Zhang

Professor

St. Jude Children's Research Hospital

UNITED STATES
View details

Andrei Thomas-Tikhonenko

Division Chief

Children's Hospital of Philadelphia

UNITED STATES
View details

Donald Parsons

Professor

Baylor College of Medicine

UNITED STATES
View details

Douglas Stewart

National Institutes of Health

UNITED STATES
View details

Poul H. Sorensen

The University of British Columbia

CANADA
View details

Joshua Schiffman

Professor

University of Utah Health

UNITED STATES
View details

Carol J Thiele

Deputy Chief

Institute of Cancer Research

UNITED STATES
View details

Andrew Wells

PROFESSOR

University of Pennsylvania

UNITED STATES
View details

Allison Pribnow

Clinical Assistant Professor

Stanford University

UNITED STATES
View details

Pandurang Kolekar

Sr. Computational Research Scientist

St. Jude Children's Research Hospital

UNITED STATES
View details

Anita Ng

Feinstein Institute for Medical Research

UNITED STATES
View details